Company limited by guarantee

Company Registration Number: 13308646 (England and Wales)

Unaudited statutory accounts for the year ended 31 March 2022

Period of accounts

Start date: 1 April 2021

End date: 31 March 2022

Contents of the Financial Statements

for the Period Ended 31 March 2022

Profit and loss

Balance sheet

Additional notes

Balance sheet notes

Community Interest Report

Profit And Loss Account

for the Period Ended 31 March 2022

	2022
	£
Turnover:	347,412
Cost of sales:	(50,170)
Gross profit(or loss):	297,242
Distribution costs:	0
Administrative expenses:	(278,886)
Other operating income:	0
Operating profit(or loss):	18,356
Interest receivable and similar income:	0
Interest payable and similar charges:	0
Profit(or loss) before tax:	18,356
Tax:	(2,602)
Profit(or loss) for the financial year:	15,754

Balance sheet

As at 31 March 2022

	Notes	2022
		£
Fixed assets		-
Tangible assets:	3	4,664
Total fixed assets:		4,664
Current assets		
Debtors:	4	1,651
Cash at bank and in hand:		32,370
Total current assets:		34,021
Prepayments and accrued income:		8,000
Creditors: amounts falling due within one year:	5	(19,659)
Net current assets (liabilities):		22,362
Total assets less current liabilities:		27,026
Accruals and deferred income:		(11,272)
Total net assets (liabilities):		15,754
Members' funds		
Profit and loss account:		15,754
Total members' funds:		15,754

The notes form part of these financial statements

Balance sheet statements

For the year ending 31 March 2022 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 5 December 2022 and signed on behalf of the board by:

Name: Dr Theresa Lawrie

Status: Director

The notes form part of these financial statements

Notes to the Financial Statements

for the Period Ended 31 March 2022

1. Accounting policies

Basis of measurement and preparation

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Notes to the Financial Statements

for the Period Ended 31 March 2022

2.	Em	pla	yees

	202
Average number of employees during the period	

Notes to the Financial Statements

for the Period Ended 31 March 2022

3. Tangible assets

	Land & buildings	Plant & machinery	Fixtures & fittings	Office equipment	Motor vehicles	Total
Cost	£	£	£	£	£	£
Additions		3,552		1,369		4,921
Disposals						
Revaluations						
Transfers						
At 31 March 2022		3,552		1,369		4,921
Depreciation						
Charge for year		125		132		257
On disposals						
Other adjustments						
At 31 March 2022		125		132		257
Net book value						
At 31 March 2022		3,427		1,237		4,664

Notes to the Financial Statements

for the Period Ended 31 March 2022

4. Debtors

	2022
	£
Other debtors	1,651
Total	1,651

Notes to the Financial Statements

for the Period Ended 31 March 2022

5. Creditors: amounts falling due within one year note

	2022
	£
Trade creditors	1,200
Taxation and social security	18,459
Total	19,659

COMMUNITY INTEREST ANNUAL REPORT

EBMCSQUARED CIC

Company Number: 13308646 (England and Wales)

Year Ending: 31 March 2022

Company activities and impact

Our collective activities are distributed through our core initiatives as follows: BiRD InternationalThis initiative's remit is to expand the use on and approval of repurposed medicines and/or integrated therapies. Advancing medical research. We convened the world's First Ivermeetin for Covid Conference on 24-25 April 2021, with talks from 11 international medical experts, attended by over 1,000 people and now publicly available online. Leading evidence synthesis. We conducted a comprehensive systematic review and meta analysis to inform guidelines for using ivermectin in clinical settings. Published in the American Journal of Therapeutics, it has been ranked 7th out of 20,432,000 articles, with 2.6 million full text views. Supporting doctors and health experts. We have helped many other doctors and health experts publish their protocols for treating and preventing Covid-19, offering professional graphic design and giving their protocols visibility on our website. Lobbying governments and health agencies. We have written to 25 administrations with a pressing recommendation to use ivermectin for the treatment of Covid-19. We believe our statements played a critical role in the development of treatment guidelines in several countries, including India. In January, 2021, we wrote to Prime Minister Boris Johnson, and in June 2021 we also wrote to June Raine, Chief Executive of the Medicines and Healthcare products Regulatory Agency, sharing an urgent preliminary report on the UK's Yellow Card data up to 26th May 2021. Providing and researching the need for vital medical care. In December 2021, our Covid care pilot identified a soaring demand for both Covid and jab injury care. Building public awareness and engagement. We have worked hard to ensure members of the public are both aware of the evidence based for ivermeetin, and also engaged them in spreading the word to health professionals, politicians, friends, family and colleagues. We've done this in the following ways: Social media. We have built a large and engaged following of 20,000 on Twitter, followed by another 25,000 on Telegram. Templates. Our letter templates were used by many as a basis for correspondence with MPs and doctors, advising them of ivermectin's effectiveness for prevention and early treatment of Covid-19. Website. In April 2021, we launched our website as a platform for sharing evidence-based information and practical advice for practitioners and individuals. The site has received 3.6 million page views, received over 600,000 visitors, sent 180,000 emails and has 10,423 subscribers. World Ivermectin Day. This international event showcased invaluable, evidence-based information about ivermectin presented by leading experts, and included success stories. The website gained 300 million web impressions, with half a million minutes of video watched. Managing enquiries from the public. We have responded to thousands of requests for information and advice from the public regarding the evidence base of ivermectin as part of early treatment of Covid-19. Addressing and correcting misinformation. We have produced over 15 letters and many rebuttals to journals challenging incorrect writings and information. As yet, none of our rebuttals have ever been challenged back by the authors. Providing expert affidavits and legal process. We regularly support requests for affidavits and evidence towards Ivermeetin-related cases in many countries. We have also been supporting an application for Judicial Review that will determine if the Government's position against ivermectin was justified and given appropriate due process. World Council for HealthLaunched in September 2021, this initiative brings together world-leading scientists, health advocates, doctors, innovators and activists working to achieve good health for all. It is now a highly popular source for health information and is freely available to the public. Sharing vital health information worldwide. We've supported over 3.6million people around the world with vital Covid-19 resources and health information to empower them to take control of their health.Producing trusted health guides. Our at home Early Treatment Guides for Covid-19 and Spike Protein Detox protocols from doctors and health experts, to help treat and prevent illness - have been downloaded more than 780,000 times. Hosting weekly open meetings. Our Monday General Assembly meetings bring together the world's leading health experts, partners and advocates and are open for all to attend, with audiences numbering in the thousands. Convening ground-breaking conferences. The first Better Way Conference brought world-leading experts, scientists and activists to Bath, UK, to brainstorm practical solutions to health and environmental challenges. Spearheading health advocacy campaigns. Our successful StopTheWHO campaign has so far activated a worldwide video response to the WHO's attempted power grab and raised awareness among politicians and citizens alike. Supporting coalition partners. We regularly collaborate with our 130+ partners on conferences and other events in countries across the globe.

Consultation with stakeholders

Since inception, we have held and supported many international meetings and medical conferences, held weekly general assembly (GA) meetings and made efforts to engage with policymakers and international health professionals. The GA meetings are open to all health professionals and the public via our newsroom and interactive chat, and coalition partner representatives are invited to express their needs and share their views during these weekly meetings. We receive regular feedback via email and other means from various stakeholders. We have conducted surveys to ascertain the needs of WCH subscribers and taken on board their feedback. Much of the feedback has been extremely positive from all stakeholders, with a great appreciation expressed about our online resources, meeting and video content, and efforts to engage leaders and the public in health promotion and positive change. Constructive feedback was also received from coalition partners on to the need to clarify the relationship between WCH and EbMCsquared CIC and improve transparency. As such, two more directors have been appointed to help with governance. Our first year accounts will be published on our website soon which will aid transparency. Much has been achieved in our first year and discussions on how best to continue to evolve the structure and direction of The company's stakeholders are BiRD coalition partners, World Council for Health coalition partners, national and subnational policy makers, health professionals, website subscribers, and members of the public. This dynamic and rapidly growing international organisation are ongoing.

Directors' remuneration

The total amount paid or receivable by directors in respect of qualifying services was £40,000.

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on

And signed on behalf of the board by: Name: Dr Theresa Lawrie Status: Director

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.